Altamira Therapeutics Ltd.
CYTO54
$0.30arrow_drop_down25.91%-$0.10
High Value
Penny Stock
CYTO54
$0.30
arrow_drop_down25.91%
There's no data available for key stats
There's no data available for ratios/profitability stats
| Fundamentals | |
|---|---|
| Gross Profit | - |
| Payout Ratio | - |
| Industry average yield | 2.89% |
| Last Dividend pay date | May 1, 2019 |
| Dividend per share | - |
| Dividend yield forecast | - |
Stock Analysis
Technicals
Summarizing what the indicators are suggesting.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Analyst rating
An aggregate view of professional's ratings.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Stock Performance
CYTO-
US Healthcare Sector-
US Market-
warning
CYTO / Market
CYTO lose to the US Market which returned 0.03% over the last twenty four hours.warning
CYTO / Healthcare Sector
CYTO lose to the US Healthcare sector which returned 2.60% over the last twenty four hours.Altamira Therapeutics Ltd. (CYTO) Statistics
Keep an eye on Altamira Therapeutics Ltd.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
How has Altamira Therapeutics Ltd. (CYTO) stock's performance compared to its sector and the market over the past year?
Over the past year, Altamira Therapeutics Ltd. (CYTO) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, Altamira Therapeutics Ltd. has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights Altamira Therapeutics Ltd.'s performance relative to both its sector and the overall market over the last year.
help
What is the PE ratio of Altamira Therapeutics Ltd. (CYTO) stock?
The PE (Price to Earnings) ratio of Altamira Therapeutics Ltd. (CYTO) is currently 0.16. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help
What is the EPS of Altamira Therapeutics Ltd. (CYTO) stock?
The Earnings Per Share (EPS) for Altamira Therapeutics Ltd. (CYTO), calculated on a diluted basis, is $1.82. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help
What is the operating margin of Altamira Therapeutics Ltd. (CYTO) stock?
The operating margin for Altamira Therapeutics Ltd. (CYTO) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help
What is the EBITDA of Altamira Therapeutics Ltd. (CYTO) stock?
The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Altamira Therapeutics Ltd. (CYTO) is $0. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help
How much debt does Altamira Therapeutics Ltd. (CYTO) have?
Altamira Therapeutics Ltd. (CYTO) has a total debt of $427.44K. The net debt for Altamira Therapeutics Ltd. (CYTO) is currently not available.